FDA supplemental approval: Acetaminophen AND Codeine Phosphate (REMS)

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) submission for acetaminophen-codeine phosphate tablets on 18 June 2026. This is a regulatory action governing post-market risk management; it does not report clinical trial results, efficacy data, or comparative safety evidence.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing acetaminophen-codeine combination product; this is a regulatory action, not a clinical efficacy trial.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This action confirms FDA approval of risk management requirements for the combination product but does not convey efficacy, safety profile, or clinical performance data. Clinicians should refer to the approved REMS protocol and product labeling for prescribing guidance and required risk minimization strategies.

Caveats

• This record does not contain clinical trial results, efficacy data, safety outcomes, or comparative efficacy evidence.
• REMS requirements are not detailed in this record; refer to FDA REMS portal for full risk management strategy.
• No information on indication, patient population studied, dosing rationale, or trial methodology is provided.
• Approval of REMS does not imply new clinical benefit or safety finding; it reflects regulatory compliance with existing product oversight.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.